Bridging the Gap Between Inpatient and Outpatient Management of Patients with COPD: Options for Long-acting Bronchodilator Therapy Webcast

Release Date: June 1, 2016
Expiration Date: June 1, 2017
Expected time to completion: 1.0 hour


Antonio Anzueto, MD
Professor of Medicine
Department of Pulmonary & Critical Care
University of Texas Health Science Center
Section Chief
Department of Pulmonary Medicine            
Audie L. Murphy Hospital
San Antonio, Texas

Medical Director
Adult Inpatient Medical Services
Presbyterian Medical Group
Central Delivery System
Albuquerque, New Mexico

Program Overview

Patients presenting to the hospital for an acute exacerbation of chronic obstructive pulmonary disease (COPD) are often previously misdiagnosed or undiagnosed altogether. Consequently, hospital-based physicians are extremely well-situated to have a significant impact on the care of these patients, not only with regard to treatment of acute exacerbations, but also in the context of long-term disease management after the patient has been stabilized. With this important responsibility comes the need for hospital physicians to be highly skilled at evaluating individuals with COPD and well-versed in information that can help patients achieve improved health outcomes and overall quality of life. The goal of the program is to provide hospitalists with the skills and information to appropriately evaluate and diagnose COPD, correctly treat patients in the acute setting, and ensure appropriate long-acting maintenance treatment is in place prior to hospital discharge.

Target Audience

This educational initiative has been designed for hospitalists involved in the care of patients with COPD.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Implement guideline-recommended strategies to accurately evaluate patients presenting with acute COPD exacerbations
  • Outline individualized treatment strategies to optimize long-term management of hospitalized patients with COPD
  • Identify strategies that reduce the risk of exacerbations and hospital readmissions for patients with COPD

Directions to Learner

There are no fees for participating and receiving CME credit for this activity. During the period June 1, 2016 through June 1, 2017, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and evaluation form

A statement of credit will be issued upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better. Your statement of credit will be sent to you within 4 weeks.



Accreditation Council for Continuing Medical Education Accreditation Statement

Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Integrity Continuing Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest (COI)

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent COI they may have as related to the content of this activity. All identified COI are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported their financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Antonio Anzueto, MD
Consulting Fees: AstraZeneca, Boehringer Ingelheim, Novartis, Sunovion Pharmaceuticals, Inc.
Contracted Research: GlaxoSmithKline

Consulting Fees: Cubist Pharmaceuticals
Ownership Interests: Gilead Sciences

Patima Tanapat, PhD, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sunovion Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Integrity Continuing Education, Inc. and Sunovion Pharmaceuticals. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Privacy Policy

When you participate in an online educational activity sponsored by Integrity CE, you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and...(continued)

Minimum System Requirements

Windows XP, Windows 2000, Windows Vista, and Windows 7
Intel Pentium 4, 2.33 + GHz (or equivalent)
Adobe® Flash® Player 10
For optimal performance, the use of Internet Explorer is not recommended.

Mac OS X v10.4 or later
1.8GHz or faster (or equivalent)
Intel Core Duo 1.33GHz or faster (or equivalent)
Adobe® Flash® Player 10

Click here for more information on minimum system requirements.


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

begin pretest


 Sponsored by Integrity Continuing Education, Inc.
Supported by an educational grant from Sunovion Pharmaceuticals, Inc.